Infantile Hemangioma Clinical Trial
Official title:
'' Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
''Evaluation of the Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
Infantile hemangiomas (IH) are benign tumors of vascular endothelium.They are the most common tumors of infancy. They occur in about 4% of infants, though early studies were as high as 10%, probably due to the inclusion of other vascular lesions. The incidence is higher in premature infants, Caucasians, and females (by a 3 to 5:1 ratio). Advanced maternal age, multiple gestations, and placental abnormalities are also risk factors. IHs have a unique and characteristic life cycle consisting of three phases: proliferative, involuting, and involuted. The majority of IHs do not require any specific treatment other than observation and reassurance of the parents. Even tumors that exhibit rapid growth or fiery red skin will spontaneously regress and leave behind little to no evidence of their presence. However, regular follow-up is important as the potential complications have few clinical indicators. Reasons for treatment include dangerous locations (impinging on a vital structure such as the airway or eye), unusually large size or rapid growth, and local or endangering complications (skin ulceration or high-output heart failure). Hemangiomas exhibiting the aforementioned risk factors or complications should be considered for treatment. As hemangiomas are tumors of pure angiogenesis, pharmacologic therapy involves angiogenesis inhibition. Historically, steroids have been used as the primary treatment for IH. Steroids have been shown to be antiangiogenic in a number of in vitro settings and also have shown good therapeutic effects clinically. However, the use of steroids may lead to various complications including gastroesophageal reflux and growth disorders, although these complications are associated with long-term use and high dose. A type of anticancer drug or immunomodulator, interferon alfa, may be used for severe IH in cases where patients did not respond to steroids. However, interferon alfa also has several possible adverse effects, including fever, muscle pain, systemic myalgia, and in severe cases, liver damage, blood toxic effects, thyroid hormonal abnormality, and neurological and neurodevelopmental toxic effects. Because of concerns about these adverse effects, many guardians of pediatric patients prefer to wait rather than accept treatment. Propranolol, a nonselective beta blocker, has recently been recognized as an important treatment option for hemangiomas. In most centers, it has become first-line pharmacotherapy. A child with a nasal capillary hemangioma treated with propranolol for steroid-induced cardiomyopathy had regression of his lesion. This revelation led to the publication of several more studies supporting this finding. Propranolol is given orally at 2-3 mg/kg/day, in two or three divided doses, and discontinued following regression of the lesion. Treatment often leads to a consistent, rapid, therapeutic effect with softening of the lesion on palpation and color shift from intense red to purple. Propranolol is well tolerated but can cause rare side effects such as bradycardia, gastroesophageal reflux, hypoglycemia, hypotension, rash, somnolence, and wheezing. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02505971 -
Nadolol Versus Propranolol in Children With Infantile Hemangiomas
|
Phase 3 | |
Recruiting |
NCT04288700 -
Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma
|
Phase 4 | |
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Completed |
NCT01010308 -
Nadolol for Proliferating Infantile Hemangiomas
|
Phase 2 | |
Completed |
NCT02913612 -
Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)
|
Phase 2 | |
Completed |
NCT01673971 -
Optical Tomographic Imaging of Infantile Hemangiomas
|
||
Recruiting |
NCT03237637 -
Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas
|
Phase 3 | |
Recruiting |
NCT05479123 -
Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas
|
Phase 4 | |
Terminated |
NCT01434849 -
Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)
|
Phase 1 | |
Completed |
NCT04105517 -
Hemangiol, Post Marketing Surveillance Study
|
||
Completed |
NCT01512173 -
Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo
|
Phase 2 | |
Completed |
NCT01056341 -
Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy
|
Phase 2/Phase 3 | |
Recruiting |
NCT03842631 -
Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination
|
||
Recruiting |
NCT03173352 -
A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China
|
N/A |